Characteristic | Initial cohort (n=17) | Validation cohort (n=15) |
---|---|---|
Age (years)* | 45 (42–50) | 45 (43–50) |
Gender (male) | 12 (60%) | 15 (83%) |
Race (African American) | 15 (75%) | 9 (50%) |
BMI | 23.7 (22.9-24.7) | 23.9 (22.7-27.2) |
HCV seropositive | 7 (41%) | 15 (100%) |
Time on ART (months)* | 30 (13–50) | 36 (16–50) |
CD4 T-cell count (cells/ul)* | 267 (107–399) | 213 (126–293) |
Nadir CD4 T-cell count (cells/ul)* | 58 (18–136) | 53 (9–132) |
Plasma HIV RNA (copies/ml)* | 69 (50–181) | 50 (50–88) |
Total Bilirubin (mg/dL)* | 0.6 (0.4-0.9) | 0.6 (0.4-0.9) |
ALT (IU/L)* | 31 (23–77) | 27 (20–38) |
AST (IU/L)* | 36 (25–59) | 33 (24–52) |
Alkaline Phosphatase (IU/L)* | 96 (81–128) | 88 (80–128) |
Albumin (g/dL)* | 4.0 (3.7-4.5) | 4.0 (3.7-4.4) |